The Oncology QCARD Initiative: Fostering efficient evaluation of initial real-world data proposals Journal Article


Authors: Rivera, D. R.; Eckert, J. C.; Rodriguez-Watson, C.; Lerro, C. C.; Bertagnolli, M. M.; Hubbard, R. A.; Kushi, L. H.; Lund, J. L.; Schrag, D.; Wang, S. V.; Wood, W. A.; Lee, J. J.; Okafor, C.; Ghauri, K.; Winckler, S. C.; Kluetz, P. G.
Article Title: The Oncology QCARD Initiative: Fostering efficient evaluation of initial real-world data proposals
Abstract: Purpose: The oncology quality, characterization, and assessment of real-world data (Oncology QCARD) Initiative was formed to develop a set of minimum study design and data elements needed to evaluate the fitness of the real-world data (RWD) source(s) proposed in an initial study concept as part of early interaction with scientific reviewers. Methods: A multidisciplinary executive committee (EC) was established to guide the Oncology QCARD Initiative. The EC conducted a landscape review of published literature, guidances, and guidelines to evaluate relevant dimensions of data quality measurement. Guided by the review and informed by expert feedback, the Oncology QCARD Initial Protocol Characterization (IPC) provides a summary of minimum elements needed to adequately describe an initial clinical study concept that involves RWD and is intended to support decision-making. Results: Fit-for-use data and fit-for-purpose design emerged as themes from the landscape analysis. Data that are fit-for-use are both relevant (sufficiently capturing exposure, outcomes, and covariates) and reliable (understanding data accrual and quality control and whether the data represent the underlying concepts they are intended to represent) to answer a specific research question. A fit-for-purpose design takes appropriate steps to ensure internal and external validity and allows for transparency in reporting. The QCARD-IPC focuses on high-level characteristics of RWD sources and study design domains including data temporality, population, medical product exposure, comparators, and covariates, endpoints, statistical analysis, and data quality assurance plans. Conclusions: Evaluation of studies including RWD requires understanding the data source, study design, and potential biases to preliminarily evaluate whether selected RWD are fit-for-use for the research question. The Oncology QCARD-IPC provides a structured, transparent approach to facilitate early review and enhanced communication between study sponsors and scientific reviewers of initial study proposals including RWD. © 2024 John Wiley & Sons Ltd. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Keywords: research design; methodology; neoplasm; neoplasms; reproducibility; quality control; clinical protocol; practice guideline; food and drug administration; oncology; feasibility study; statistical analysis; clinical study; publishing; medical research; data analysis; medical oncology; medical literature; reliability; feedback system; decision making; study design; external validity; internal validity; clinical outcome; clinical significance; humans; human; article; evaluation study; best practice; common data elements; multidisciplinary team; real-world data; real-world evidence; data quality; data accuracy; data availability; patient guidance; data completeness; health data; data source; fit-for-purpose; observational study design
Journal Title: Pharmacoepidemiology and Drug Safety
Volume: 33
Issue: 11
ISSN: 1053-8569
Publisher: John Wiley & Sons  
Date Published: 2024-11-01
Start Page: e5818
Language: English
DOI: 10.1002/pds.5818
PUBMED: 39462868
PROVIDER: scopus
DOI/URL:
Notes: Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Deborah Schrag
    229 Schrag